935.00
0.00
(0.00%)
At close: October 30 at 12:48:46 PM CST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 1 | 19 | 18 |
| Avg. Estimate | 13.67B | 16.67B | 66.65B | 65.63B |
| Low Estimate | 11.35B | 16.67B | 62.45B | 62.72B |
| High Estimate | 15.99B | 16.67B | 70.41B | 71.8B |
| Year Ago Sales | 13.02B | 20.75B | 66.06B | 66.65B |
| Sales Growth (year/est) | 4.99% | -19.66% | 0.89% | -1.53% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| HBCN.MX | -- | -- | -- | -- |
| S&P 500 | 9.26% | 11.36% | 13.91% | 13.52% |
Upgrades & Downgrades
| Downgrade | Barclays: Overweight to Equal-Weight | 3/27/2024 |
| Downgrade | Goldman Sachs: Buy to Neutral | 8/4/2022 |
| Downgrade | Exane BNP Paribas: Outperform to Neutral | 8/2/2022 |
| Upgrade | UBS: Neutral to Buy | 10/6/2021 |
| Upgrade | Credit Suisse: Underperform to Neutral | 3/16/2021 |
| Upgrade | RBC Capital: Underperform to Sector Perform | 2/9/2021 |